AIM: To investigate the chemical constituents of aerial parts of Gynura divaricata(L.)DC.METHODS: Chemical constituents were isolated with multi-chromatographic methods.Their structures were determined by spectral ana...AIM: To investigate the chemical constituents of aerial parts of Gynura divaricata(L.)DC.METHODS: Chemical constituents were isolated with multi-chromatographic methods.Their structures were determined by spectral analysis and chemical evidence.RESULTS: 10 compounds were obtained and identified as quercetin(Ⅰ),3-O-β-Dglucopyranosyl quercetin(Ⅱ),3-O-β-D-(6→1) glucopyranosyl-αL-rhamnosyl quercetin(Ⅲ),3-O-β-D-(6→1)glucopyranosyl-α-L-rhamnosyl kaemferol(Ⅳ),epi-friedelinol(Ⅴ),epi-friedelinol acetatd(Ⅵ),β-sitosterol(Ⅶ),stigmasterol(Ⅷ),adenosine(Ⅸ) and uridine(Ⅹ).CONCLUSION: All these compounds were isolated from this plant for the first time.展开更多
Hepatitis B virus （HBV） infection is still the most common cause of hepatocellular carcinoma and liver drrhosis world wide. Recently, however, there has been quite dramatic improvement in the understanding of HBV as...Hepatitis B virus （HBV） infection is still the most common cause of hepatocellular carcinoma and liver drrhosis world wide. Recently, however, there has been quite dramatic improvement in the understanding of HBV assodated liver disease and its treatment. It has become dear that high viral replication is a major risk factor for the development of both cirrhosis and hepatocellular carcinoma. Early studies have shown lamivudine lowers the risk of HBV associated complications. There are currently three nucleos（t）ides licensed, in addition to interferon, and there are more drugs coming to the market soon. Interferon or its pegylated counterpart are still the only options for treatment with defined end points, while nudeos（t）ides therapy is used mostly for long term treatment. Combination therapies have not been shown to be superior to monotherapy in naive patients, however, the outcome depends on how the end point is defined. Interferon plus lamivudine achieves a higher viral suppression than either treatment alone, even though Hbe-seroconversion was not different after a one year treatment. HBV-genotypes emerge as relevant factors, with genotypes ＂A＂ and ＂B＂ responding relatively well to interferon, achieving up to 20% HBsAg clearance in the case of genotype ＂A＂. In addition to having a defined treatment duration, interferon has the advantage of lack- ing resistance selection, which is a major drawback for lamivudine and the other nucleos（t）ides. The emergence of resistance against adefovir and entecavir is some- what slower in na＇fve compared to lamivudine resistant patients. Adefovir has a low resistance profile with 3%, 9%, 18%, and 28% after 2, 3, 4, and 5 years, respectively, while entecavir has rarely produced resistance in naive patients for up to 3 years.展开更多
AIM:To investigate the survival rates and prognostic factors in patients with hepatitis B virus-related acuteon-chronic liver failure(HBV-ACLF).METHODS:Clinical data in hospitalized patients with HBV-ACLF admitted fro...AIM:To investigate the survival rates and prognostic factors in patients with hepatitis B virus-related acuteon-chronic liver failure(HBV-ACLF).METHODS:Clinical data in hospitalized patients with HBV-ACLF admitted from 2006 to 2009 were retrospectively analyzed.Their general conditions and survival were analyzed by survival analysis and Cox regression analysis.RESULTS:A total of 190 patients were included in this study.The overall 1-year survival rate was 57.6%.Patients not treated with antiviral drugs had a significantly higher mortality[relative risk(RR)=0.609,P=0.014].The highest risk of death in patients with ACLF was associated with hepatorenal syndrome(HRS)(RR=2.084,P=0.026),while other significant factors were electrolyte disturbances(RR=2.062,P=0.010),and hepatic encephalopathy(HE)(RR=1.879,P<0.001).CONCLUSION:Antiviral therapy has a strong effect on the prognosis of the patients with HBV-ACLF by improving their 1-year survival rate.HRS,electrolyte disturbances,and HE also affect patient survival.展开更多
文摘AIM: To investigate the chemical constituents of aerial parts of Gynura divaricata(L.)DC.METHODS: Chemical constituents were isolated with multi-chromatographic methods.Their structures were determined by spectral analysis and chemical evidence.RESULTS: 10 compounds were obtained and identified as quercetin(Ⅰ),3-O-β-Dglucopyranosyl quercetin(Ⅱ),3-O-β-D-(6→1) glucopyranosyl-αL-rhamnosyl quercetin(Ⅲ),3-O-β-D-(6→1)glucopyranosyl-α-L-rhamnosyl kaemferol(Ⅳ),epi-friedelinol(Ⅴ),epi-friedelinol acetatd(Ⅵ),β-sitosterol(Ⅶ),stigmasterol(Ⅷ),adenosine(Ⅸ) and uridine(Ⅹ).CONCLUSION: All these compounds were isolated from this plant for the first time.
基金Supported by the German BMBF and Network for competence in viral hepatitis
文摘Hepatitis B virus （HBV） infection is still the most common cause of hepatocellular carcinoma and liver drrhosis world wide. Recently, however, there has been quite dramatic improvement in the understanding of HBV assodated liver disease and its treatment. It has become dear that high viral replication is a major risk factor for the development of both cirrhosis and hepatocellular carcinoma. Early studies have shown lamivudine lowers the risk of HBV associated complications. There are currently three nucleos（t）ides licensed, in addition to interferon, and there are more drugs coming to the market soon. Interferon or its pegylated counterpart are still the only options for treatment with defined end points, while nudeos（t）ides therapy is used mostly for long term treatment. Combination therapies have not been shown to be superior to monotherapy in naive patients, however, the outcome depends on how the end point is defined. Interferon plus lamivudine achieves a higher viral suppression than either treatment alone, even though Hbe-seroconversion was not different after a one year treatment. HBV-genotypes emerge as relevant factors, with genotypes ＂A＂ and ＂B＂ responding relatively well to interferon, achieving up to 20% HBsAg clearance in the case of genotype ＂A＂. In addition to having a defined treatment duration, interferon has the advantage of lack- ing resistance selection, which is a major drawback for lamivudine and the other nucleos（t）ides. The emergence of resistance against adefovir and entecavir is some- what slower in na＇fve compared to lamivudine resistant patients. Adefovir has a low resistance profile with 3%, 9%, 18%, and 28% after 2, 3, 4, and 5 years, respectively, while entecavir has rarely produced resistance in naive patients for up to 3 years.
基金Supported by National 11th Five-Year Special Major Project for Infectious Diseases(No.2008zx10002-005-6)Collaborative Project between US and China on Major Liver Diseases(No. 2009DFA32450)+1 种基金The Capital Medical Research and Development(No.20072026)the Army Medical and Health Scientific Research Fund of China,No.06H057
文摘AIM:To investigate the survival rates and prognostic factors in patients with hepatitis B virus-related acuteon-chronic liver failure(HBV-ACLF).METHODS:Clinical data in hospitalized patients with HBV-ACLF admitted from 2006 to 2009 were retrospectively analyzed.Their general conditions and survival were analyzed by survival analysis and Cox regression analysis.RESULTS:A total of 190 patients were included in this study.The overall 1-year survival rate was 57.6%.Patients not treated with antiviral drugs had a significantly higher mortality[relative risk(RR)=0.609,P=0.014].The highest risk of death in patients with ACLF was associated with hepatorenal syndrome(HRS)(RR=2.084,P=0.026),while other significant factors were electrolyte disturbances(RR=2.062,P=0.010),and hepatic encephalopathy(HE)(RR=1.879,P<0.001).CONCLUSION:Antiviral therapy has a strong effect on the prognosis of the patients with HBV-ACLF by improving their 1-year survival rate.HRS,electrolyte disturbances,and HE also affect patient survival.
